BLTE

Business Context and Reporting Period

Company: Belite Bio, Inc. (BLTE)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Belite Bio is a clinical-stage biopharmaceutical company developing novel therapeutics for degenerative retinal diseases. Its lead product candidate, tinlarebant (LBS-008), is an oral RBP4 antagonist targeting Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA). A second candidate, LBS-009, is in preclinical development for metabolic diseases.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The company has no debt and no revenue. Expenses are primarily driven by clinical trial costs and share-based compensation.

Material Changes vs. Prior Period

• Expense Surge: Total operating expenses more than doubled to $84.2 million. SG&A expenses increased by 286% primarily due to a $24.6 million increase in share-based compensation and higher professional fees. R&D expenses rose 52% due to the PHOENIX trial (GA), API manufacturing, and increased share-based compensation.
• Capital Raising: The company significantly strengthened its liquidity position through multiple financing activities in 2025, including a $350 million underwritten public offering (with full over-allotment exercise), a $125 million PIPE offering, and registered direct offerings. Net cash provided by financing activities was $663.2 million.
• Clinical Milestones: In December 2025, the company announced positive top-line results from the Phase 3 DRAGON trial for STGD1, showing a 35.7% reduction in lesion growth. The company expects to submit a New Drug Application (NDA) to the FDA in Q2 2026.
• Share-Based Compensation: Total share-based compensation expense jumped to $38.9 million in 2025 from $9.0 million in 2024, driven by significant grants to management and employees.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue incurring significant operating losses as it advances tinlarebant toward regulatory approval and commercialization. The company believes its current cash and investment portfolio ($772.6 million in total liquid assets) is sufficient to fund operations for at least the next 12 months.
• Regulatory Path: The company anticipates submitting an NDA for tinlarebant for STGD1 in Q2 2026. The Phase 3 PHOENIX trial for GA is ongoing with enrollment complete (530 subjects).
• Key Risks:
  • Development Risk: Success is highly dependent on the approval and commercialization of tinlarebant. Failure in clinical trials or regulatory rejection would materially harm the business.
  • Financial Risk: The company has a history of net losses and requires additional financing to fund future operations and commercialization efforts.
  • Intellectual Property: The company relies on an exclusive license from Columbia University; failure to meet milestones could result in license termination.
  • Geopolitical/Regulatory: Operations in China and reliance on global CROs expose the company to regulatory changes, data transfer restrictions, and geopolitical tensions.

Investor Verification Checklist

• NDA Submission Timeline: Verify the Q2 2026 NDA submission date for tinlarebant (STGD1) and monitor for any FDA feedback or delays.
• Cash Burn Rate: Monitor quarterly cash usage to confirm the "12-month runway" assertion remains valid given the high burn rate ($40.7M operating cash outflow in 2025).
• Share-Based Compensation: Review future equity grant plans, as the $38.9M expense in 2025 significantly impacted net loss and may indicate future dilution.
• PHOENIX Trial Data: Await interim or top-line data from the Phase 3 PHOENIX trial for Geographic Atrophy to assess the broader commercial potential of tinlarebant.
• Columbia University License: Confirm compliance with development milestones to avoid license conversion or termination.